☆ 4.5 Article

Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study

ADVANCES IN THERAPY (2022)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study

Simone Parisi et al.

Summary: This study evaluated the long-term drug survival and efficacy of the biosimilar SB4/Benepali in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) patients. The results showed that SB4 had similar efficacy and long-term retention in these patients, with a good safety profile.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Rheumatology

Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naive to or switched from biologics

Tsutomu Takeuchi et al.

Summary: The post-marketing surveillance study evaluated the safety and efficacy of CT-P13, the first biosimilar of IFX, in real-world settings. CT-P13 showed excellent effectiveness as first-line therapy and clinical improvement in patients who switched from IFX or other bDMARDs. CT-P13 could be a cost-effective alternative to IFX in the treatment of rheumatoid arthritis.

MODERN RHEUMATOLOGY (2022)

Add to Collection

Article Rheumatology

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study

Dimitrios A. Pappas et al.

Summary: The study found no significant differences in outcomes between TNFi and non-TNFi treatment groups for rheumatoid arthritis patients in US clinical practice. This supports RA guidelines that recommend individualized care based on clinical judgment and patient preferences.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Pharmacology & Pharmacy

Doctor's aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center

Omar Al Tabaa et al.

Summary: This study aimed to describe the switch from iETN to bETN, evaluate factors associated with the switch, and assess the efficacy of the switch. Findings suggest that physician age and position may influence the likelihood of patients switching to bETN. After 6 months of follow-up, the bETN retention rate was 83%.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Article Rheumatology

Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA

Xiaomeng Yue et al.

Summary: In newly diagnosed JIA patients, TNFi showed better persistence and effectiveness compared to non-TNFi. TNFi had significantly longer persistence than non-TNFi in the first bDMARD course. Additionally, TNFi users had significantly greater reduction in clinical Juvenile Disease Activity Score (cJADAS) at the 6-month follow-up compared to non-TNFi users.

RHEUMATOLOGY (2021)

Add to Collection

Review Rheumatology

The Prevalence of Rheumatoid Arthritis: A Systematic Review of Population-based Studies

Khalid B. Almutairi et al.

Summary: The prevalence of rheumatoid arthritis varies widely based on population and data collection methods, with an average point prevalence of 51 in 10,000 and average period prevalence of 56 in 10,000. Urban settings tend to have higher RA prevalence than rural areas, potentially due to differences in healthcare access or risk environment. Studies using population databases and validated diagnoses by rheumatologists are more consistent in estimating RA prevalence.

JOURNAL OF RHEUMATOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

HoUng Kim et al.

DRUGS (2020)

Add to Collection

Review Cell Biology

Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis

Yen-Ju Lin et al.

CELLS (2020)

Add to Collection

Article Rheumatology

The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases

Cosimo Bruni et al.

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2020)

Add to Collection

Article Rheumatology

Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)

Marc Scherlinger et al.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)

Add to Collection

Article Rheumatology

Are There Benefits and Risks to Biosimilars from a Patient Perspective?

Jonathan Kay

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2019)

Add to Collection

Article Biochemical Research Methods

Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis - A comparison in a real-world national cohort

Catalin Codreanu et al.

BIOLOGICALS (2019)

Add to Collection

Article Rheumatology

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

Bente Glintborg et al.

ANNALS OF THE RHEUMATIC DISEASES (2019)

Add to Collection

Review Rheumatology

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naive or Switching Patients: A Systematic Review

Hans C. Ebbers et al.

RHEUMATOLOGY AND THERAPY (2019)

Add to Collection

Review Medicine, Research & Experimental

Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review

Paul Emery et al.

ADVANCES IN THERAPY (2018)

Add to Collection

Article Rheumatology

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4

Paul Emery et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

Add to Collection

Article Rheumatology

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Jasvinder A. Singh et al.

ARTHRITIS CARE & RESEARCH (2016)

Add to Collection

Article Immunology

Epidemiology of adult rheumatoid arthritis

Y Alamanos et al.

AUTOIMMUNITY REVIEWS (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.